Navigation Links
Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
Date:8/5/2009

SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today reported financial results for the second quarter ended June 30, 2009. Optimer reported a net loss for the second quarter of 2009 of $12.4 million, or $0.37 per share, which was in line with the Company's expectations. This compares to a net loss for the second quarter of 2008 of $8.1 million, or $0.29 per share. The increase in net loss was primarily due to higher research and development expenses. Research and development expenses in the second quarter of 2009 were $10.5 million, compared to $6.2 million in the second quarter of 2008. The increase was primarily due to manufacturing scale-up expenses and expenses to prepare regulatory filings related to the Company's fidaxomicin and prulifloxacin programs.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

As of June 30, 2009, Optimer held cash, cash equivalents and short-term investments of $51.2 million.

"During the second quarter, we had the first oral presentations of our North American Phase 3 fidaxomicin data at major scientific conferences showing that fidaxomicin is more effective than oral vancomycin when it comes to reducing recurrence of CDI, even in high risk patient populations," said Michael N. Chang, Ph.D., Optimer's President and Chief Executive Officer. "As we head into the second half of this year, we look forward to presenting additional data from this study at ICAAC and IDSA and we are focused on completing our second fidaxomicin Phase 3 trial and preparing regulatory filings for fidaxomicin and prulifloxacin."

Recent Corporate Highlights

  • Clinical inves
    '/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
2. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
3. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
4. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
5. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
6. Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
8. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
9. Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level
10. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
11. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... 27, 2014 The new research ... (High & Medium), Sub-type (Primary & Secondary), and ... & Transportation & Power Generation) - Trends and ... market with analysis and forecasting of the market ... Tables with 52 Figures spread through 146 Pages ...
(Date:10/27/2014)... TORONTO , Oct. 27, 2014 ... (OTCQB: GNBT) today announced two presentations demonstrating that ... its novel proprietary cancer immunotherapeutic AE37 vaccine correlated ... patients. The AE37 cancer vaccine is being developed ... ( www.antigenexpress.com ). The presentations are being made ...
(Date:10/27/2014)... 27, 2014 The “Molecular Diagnostic ... Microbiology), Technology (PCR, INAAT, DNA Sequencing), End User ... Software) - Global Forecast to 2018” provides a ... opportunities, current market trends, and strategies impacting the ... and forecasts of the revenue and share analysis. ...
(Date:10/27/2014)... 27, 2014 Called the NOAH ... eliminating several types of pediatric brain cancer. The ... in over 30 years of research and development. ... proves that one mom's determination can make a ... Halloween trick-or-treating, and it’s only fitting that we’ve ...
Breaking Biology Technology:Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 5FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3
... Calif., Feb. 17 Avantis Medical Systems, Inc., a ... announced today that it has received a new 510(k) ... the claim for increased detection of cancerous and pre-cancerous ... technology that has been cleared by the FDA to ...
... as Senior Scientist , BURLINGTON, Mass., ... expansion of its executive team with the appointment ... The company also announced the addition of Richard ... )The appointments reflect the evolution of the company,s ...
... LIMMERICK, Ireland, Feb. 16 Copan Innovation Ltd., whose ... collection and transport systems in the world, has named ... Development in the Pacific Rim, as well as appointed ... Innovation Ltd. Bob Cooper, who brings a background of ...
Cached Biology Technology:Avantis Medical Systems Announces FDA 510(k) Clearance for the Third Eye(R) Retroscope(R) for Improved Polyp Detection in the Colon 2Avantis Medical Systems Announces FDA 510(k) Clearance for the Third Eye(R) Retroscope(R) for Improved Polyp Detection in the Colon 3Avantis Medical Systems Announces FDA 510(k) Clearance for the Third Eye(R) Retroscope(R) for Improved Polyp Detection in the Colon 4CorNova(R) Expands Management Team with Appointment of Robert Gallahue as Chief Financial Officer 2Copan Announces the Appointment of Bob Cooper as Vice President of Business Development in the Pacific Rim 2
(Date:10/29/2014)... of kidney cancer patients in Europe sheds light on ... an apparent link between exposure to aristolochic acid and ... research, by an international team led by scientists from ... Montreal, underscores the importance of investigating possible sources of ... of the Aristolochia genus, also has been suspected of ...
(Date:10/28/2014)... German . , ... food when times are lean? By studying wild chimpanzees ... of the Max Planck Institute for Evolutionary Anthropology in ... apes can acquire extra energy needed to maintain large, ... nests more en route to breakfast sites containing fruits ...
(Date:10/28/2014)... of Health (NIH) announced awards to expand the ... National Center for Advancing Translational Sciences (ORDR-NCATS) collaborative ... the network, physician scientists at 22 consortia will ... clinical research and investigate new treatments for patients ... by $29 million in fiscal 2014 funding from ...
Breaking Biology News(10 mins):Study sheds light on genetic architecture of kidney cancer 2Study sheds light on genetic architecture of kidney cancer 3The early chimp gets the fig 2The early chimp gets the fig 3NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3
... IN Traditional turfgrass management programs rely heavily ... In response to increased public scrutiny and legislation, ... but research indicates that these alternatives have not ... lawn care industry. Results of a new study ...
... as the great pandemia of the XXI century. Recent data ... suffering from overweight, of which 300 million are clinically obese. ... worrying increase, with more than 155 million children and adolescents ... Biologist Aline Jelenkovic analysed to what point corporal morphology was ...
... QUEBEC, CANADA A study in HortTechnology ... reducing solar heat radiation and temperatures during the hot ... Canadian researchers, was the first investigation into the effects ... shading method. Results showed that the technology improved greenhouse ...
Cached Biology News:Turfgrass fertility, pesticide programs compared 2The amount of adipose tissue should be taken into account in the fight against obesity 2The amount of adipose tissue should be taken into account in the fight against obesity 3New technology improves greenhouse, plant microclimates 2
FluoSpheres® biotin-labeled microspheres, 1.0 µm, yellow-green fluorescent (505/515) *1% solids*...
chk 1 kinase...
muscle actin (HUC1-1)...
... Neural Stem Cell Functional Identification Kit ... can be used for the short-term ... and the induction of NSCs into ... antibody panel consisting of mouse anti-human ...
Biology Products: